

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Steven I. Goldstein		
Signature		Date	March 21, 2003
<b>INFORMATION DISCLOSURE STATEMENT</b>		Attorney Docket	IRVN-007CON2
		First Named Inventor	GATANAGA, TETSUYA
		Application Number	09/752,639
		Filing Date	December 29, 2000
		Group Art Unit	1646
		Examiner Name	MURPHY, JOSEPH F.
		Title:	"SCREENING FOR DRUGS THAT AFFECT INF RELEASING ENZYME"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. This is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in §1.491 in an international application or *after* the mailing date of the first Office Action on the merits, whichever event occurred last, but *before* the mailing date of either a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

A Form PTO-SB/08A listing the references accompanies this paper. Applicants would appreciate the Examiner's initiating and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein are being submitted prior to the final determination on patentability by the Office.

All of the references identified herein were cited in an International (PCT) Search Report dated \*, in a PCT application corresponding to the above-identified U.S. application. A copy of the Search Report, including an indication of the purported relevance of the cited documents, is enclosed herewith. Copies of the references are submitted herewith.

All of the references identified herein were disclosed in parent application Serial No. 09/712,813 and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d), except if noted below.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

MAY-13-03 TUE 01:22 PM

FAX NO.

P. 23


Atty Dkt. No.: IRVN-007CON2  
USSN: 09/752,639

Please charge the \$180.00 fee required by 37 C.F.R. §1.97(c) and set forth in 37 C.F.R. 1.17(p) and any additional fees which may be required by this paper or any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21, or to credit any overpayment, to Deposit Account No. 50-0815, order number IRVN-007CON2.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: March 21, 2003

By:

  
Carol L. Francis  
Registration No. 30,513

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231